Enric Carcereny News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Immutep s Efti Proves Effective Combined with MSD s Pembrolizumab

Immutep s Efti Proves Effective Combined with MSD s Pembrolizumab
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Marc voigtEnric carcerenyCatalan institute of oncologyCatalan institute

Immutep s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not been reached in patients with high PD-L1 expression (TPS >50%), exceeding expectationsPromising Overall Survival, Overall Response Rate, Progression Free Survival, and Duration of Response visible across all PD-L1 subgroups (TPS <1%, ≥1%, 1-49%, and ≥50%), differen

Comunidad autonoma de catalunaUnited statesNew south walesFrederic triebelChristian muellerFlorian voglMarc voigtChris bastaEnric carcerenyCatalan institute of oncologyDrug administrationMerck sharp dohmeCorporate communicationsStrategic developmentImmutep limitedMerck co inc

GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) -October 23, 2023 at 08:28 am EDT

GALLANT-1: GB1211 Galectin-3 inhibitor plus atezolizumab for first line treatment in patients .

Comunidad autonoma de catalunaFrance generalIsrael generalRodryg ramlauAshfield medcommsEnriqueta felipEnric carcerenyZahir rajiwateEric pichonBiomarcadoresy medicinaLinda basseChemother pharmacolTariq sethiAlison mackinnonPia jensenBertil lindmark

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Media ReleaseNew updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Satur.

New south walesUnited statesEnric carcerenyChris bastaFlorian voglKatarzyna kozakChristian muellerFrederic triebelMarc voigtKrankenhaus nordwestCatalan institute of oncologyMerck co incStrategic developmentImmutep limitedCurie national research institute of oncologyCorporate communications

Immutep : to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023

Media Release Mini Oral presentation will include datafromTACTI-002 Phase II trialevaluating chemotherapy-free IO combination of efti plus KEYTRUDA® .

United statesComunidad autonoma de catalunaNew south walesEnric carcerenyChris bastaMerck coDrug administrationMerck co incMerck sharp dohmeCorporate communicationsCatalan institute of oncologyImmutep limitedEuropean society for medical oncologyFrankfurt institute of clinical cancer researchMini oralMedical oncology